Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

KPTI Karyopharm Therapeutics Inc

Price (delayed)

$4.49

Market cap

$38.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.17

Enterprise value

$186.37M

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related ...

Highlights
The net income has soared by 57% YoY and by 18% from the previous quarter
The EPS has soared by 57% YoY and by 14% from the previous quarter
KPTI's debt is up by 6% YoY but it is down by 4% from the previous quarter
Karyopharm Therapeutics's quick ratio has plunged by 58% YoY and by 23% from the previous quarter
The equity has contracted by 22% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of KPTI
Market
Shares outstanding
8.64M
Market cap
$38.79M
Enterprise value
$186.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.31
Earnings
Revenue
$142.13M
Gross profit
$136.73M
Operating income
-$118.94M
Net income
-$62.52M
EBIT
-$19.97M
EBITDA
-$19.64M
Free cash flow
-$122.69M
Per share
EPS
-$8.17
EPS diluted
-$13.27
Free cash flow per share
-$14.49
Book value per share
-$24.46
Revenue per share
$16.78
TBVPS
$15.08
Balance sheet
Total assets
$127.71M
Total liabilities
$333.6M
Debt
$186.7M
Equity
-$205.88M
Working capital
$29.87M
Liquidity
Debt to equity
-0.91
Current ratio
1.33
Quick ratio
1.17
Net debt/EBITDA
-7.52
Margins
EBITDA margin
-13.8%
Gross margin
96.2%
Net margin
-44%
Operating margin
-83.7%
Efficiency
Return on assets
-36%
Return on equity
N/A
Return on invested capital
-8.8%
Return on capital employed
-53.5%
Return on sales
-14%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KPTI stock price

How has the Karyopharm Therapeutics stock price performed over time
Intraday
5.4%
1 week
6.9%
1 month
-28.39%
1 year
-69.23%
YTD
-55.72%
QTD
20.05%

Financial performance

How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$142.13M
Gross profit
$136.73M
Operating income
-$118.94M
Net income
-$62.52M
Gross margin
96.2%
Net margin
-44%

KPTI financials

KPTI's net margin has soared by 58% YoY and by 16% from the previous quarter
The net income has soared by 57% YoY and by 18% from the previous quarter
KPTI's operating margin is up by 11% YoY
KPTI's operating income is up by 10% YoY

Price vs fundamentals

How does KPTI's price correlate with its fundamentals

KPTI Price vs fundamentals

KPTI Earnings waterfall

KPTI Price vs fair value

Growth

What is Karyopharm Therapeutics's growth rate over time

KPTI growth chart

Valuation

What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.31

Valuation vs average

Price to earnings (P/E)

The EPS has soared by 57% YoY and by 14% from the previous quarter

Price to book (P/B)

The equity has contracted by 22% YoY and by 11% from the previous quarter

Price to sales (P/S)

The P/S is 93% lower than the 5-year quarterly average of 3.8 and 55% lower than the last 4 quarters average of 0.6
The revenue has contracted by 2.1% from the previous quarter

Efficiency

How efficient is Karyopharm Therapeutics business performance
The ROS has soared by 84% YoY and by 48% from the previous quarter
Karyopharm Therapeutics's return on invested capital has surged by 77% YoY and by 43% QoQ
KPTI's ROA is up by 38% YoY and by 9% QoQ

Dividends

What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KPTI.

Financial health

How did Karyopharm Therapeutics financials performed over time

Assets vs liabilities

KPTI's total assets is 62% smaller than its total liabilities
Karyopharm Therapeutics's quick ratio has plunged by 58% YoY and by 23% from the previous quarter
The current ratio has plunged by 56% YoY and by 22% from the previous quarter

Debt vs equity

KPTI's debt is 191% more than its equity
The equity has contracted by 22% YoY and by 11% from the previous quarter
KPTI's debt to equity is up by 13% since the previous quarter and by 13% year-on-year

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.